Early testing indicates that the mutations in the Omicron variant of coronavirus may hamper the ability of Regeneron’s antibody drug to treat Covid-19, the company said, indicating that some therapies may have to be adapted to tackle the virus’s latest evolution.
The findings are a first indication that treatments developed to tackle Covid-19 may have lost effectiveness as the virus evolves. “The individual mutations present in the Omicron variant indicate that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity,” Regeneron said on Tuesday.
您已阅读39%（604字），剩余61%（937字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。